Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Molecular recognition scaffolds

Molecular recognition scaffolds

Company Platform technology Disease areas Targets Status (Next milestone)
Ablynx Founded: 2002 Money raised: $35M Headcount (R&D/Total): 27/35 Nanobodies: Single-domain antibodies from the camelid family. Delivery options: oral and injectable. Manufactured using bacteria and yeast cultures. Autoimmune; inflammation; cancer TNF alpha; von

Read the full 479 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers